ITGA2 was significantly upregulated in high-grade serous ovarian cancers compared with normal counterparts, and overexpressed ITGA2 contributed to paclitaxel resistance via activation of the AKT pathway in ovarian cancer cells [56, 57]. This evidence concerns the gene AKT1 and ovarian cancer.